Anti-CD257 [I116A01 (Belimumab)]

Catalogue Number: AB04179-10.0-ABA

Manufacturer:	Vector Laboratories, Inc (ABA)
Type:	Recombinant Monoclonal
Shipping Condition:	Blue Ice
Unit(s):	100 ug
Host name:	Human
Clone:	I116A01 (Belimumab)
Isotype:	IgG1
Immunogen:	The original antibody was isolate from a nonimmunized human scFv phage display library by 3 rounds of panning against human BLyS. Later on the human IgG1 version of the antibody was generated by separate cloning of heavy and light chain into expression vectors and transfection of mammalian cells like HEK293 or NSO to produce whole IgG.
Application:	ELISA, FC, Inh

Overview
Datasheets

Additional Text

Gene Name

TNFSF13B

Gene ID

10673

Uniprot ID

Q9Y275

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.

Application Notes

The binding reactivity of this antibody to human BLyS was tested using ELISA. The human IgG1 version of this antibody binds human BLyS with an EC50 value of 0.024 nM. This antibody can bind BLyS in both a solid-phase capture assay and in solution. The binding of this antibody to membrane-bound BLyS expressed on surface of primary human cells and K562 myelogenous leukemia cell line was determined using flow cytometry. This antibody was reported to inhibit binding of BLyS to its receptors TACI, BCMA, and BR-3 with equivalentpotency of IC50 0.10-0.11 nM in an electrochemiluminescence detection assay. The inhibitory activity towards receptors was further confirmed using cell-based assay where full-length TACI, BCMA, and BR-3 were transiently expressed on the surface of HEK293T cells (PMID: 14613291). This antibody potently inhibited BLyS induced proliferation of B cells in vitro, and its administration to mice prevented human BLyS-induced increases in splenic B cell numbers and IgA titers. In cynomolgus monkeys, administration of this antibody resulted in decreased B cell representation in both spleen and mesenteric lymph nodes (PMID: 14613291). The safety and efficacy of this antibody was studied in a randomized, placebo-controlled group of patients with active systemic lupus erythematosus (SLE). It was reported that belimumab has the potential to be the first targeted biological treatment for management of systemic lupus erythematosus (PMID: 21296403). Another phase III clinical trial study concluded that belimumab may offer renal benefit in patients with SLE (PMID: 23263865).

Specificity

BAFF; BLyS; TNFSF13B; TALL-1; TNFSF20; ZTNF4; Tumor necrosis factor ligand superfamily member 13B; B lymphocyte stimulator; B-cell-activating factor; Dendritic cell-derived TNF-like molecule; TNF and APOL-related leukocyte expressed ligand 1; LymphoStat-B; hBLySmAb-1.1; anti-BLyS-I116A01; PTA-3240; NSO-anti-BLyS-116A01-60

AB04179-10.0 Datasheet

Price

£430.00

-

Quantity
Unit Size

Find out about delivery